175 related articles for article (PubMed ID: 19887725)
21. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urodynamic study.
Matsukawa Y; Takai S; Funahashi Y; Kato M; Yamamoto T; Gotoh M
Neurourol Urodyn; 2017 Mar; 36(3):748-754. PubMed ID: 27060991
[TBL] [Abstract][Full Text] [Related]
23. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.
Verheggen BG; Lee R; Lieuw On MM; Treur MJ; Botteman MF; Kaplan SA; Trocio JN
J Med Econ; 2012; 15(3):586-600. PubMed ID: 22332704
[TBL] [Abstract][Full Text] [Related]
24. A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.
Cao Y; Wang Y; Guo L; Yang X; Chen T; Niu H
Med Sci Monit; 2016 Jun; 22():1895-902. PubMed ID: 27260129
[TBL] [Abstract][Full Text] [Related]
25. Effects of propiverine and naftopidil on the urinary ATP level and bladder activity after bladder stimulation in rats.
Sugaya K; Nishijima S; Tasaki S; Kadekawa K; Miyazato M; Ogawa Y
Neurosci Lett; 2007 Dec; 429(2-3):142-6. PubMed ID: 17997223
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochloride.
Kawachi Y; Sakurai T; Sugimura S; Iwata S; Noto K; Honda S; Maruyama O
Scand J Urol Nephrol; 2010 Feb; 44(1):38-45. PubMed ID: 20095868
[TBL] [Abstract][Full Text] [Related]
27. Investigating the associations of mucosal P2Y6 receptor expression and urinary ATP and ADP concentrations, with symptoms of overactive bladder.
Firouzmand S; Ajori L; Towse J; Allameh F; Najafi S; Javed S; John B; Langley SEM; Fry CH; Young JS
Neurourol Urodyn; 2020 Mar; 39(3):926-934. PubMed ID: 32049380
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.
Lojanapiwat B; Permpongkosol S
Int Braz J Urol; 2011; 37(4):468-76. PubMed ID: 21888698
[TBL] [Abstract][Full Text] [Related]
29. [Latest frontiers in pharmacotherapy for benign prostatic hyperplasia].
Kawabe K
Yakugaku Zasshi; 2006 Mar; 126 Spec no.():199-206. PubMed ID: 16518083
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial.
Djavan B; Shariat S; Fakhari M; Ghawidel K; Seitz C; Partin AW; Roehrborn CG; Marberger M
Urology; 1999 Feb; 53(2):251-9. PubMed ID: 9933035
[TBL] [Abstract][Full Text] [Related]
31. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
32. Safety of anticholinergics in patients with benign prostatic hyperplasia.
Athanasopoulos A; Mitropoulos D; Giannitsas K; Perimenis P
Expert Opin Drug Saf; 2008 Jul; 7(4):473-9. PubMed ID: 18613810
[TBL] [Abstract][Full Text] [Related]
33. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
[TBL] [Abstract][Full Text] [Related]
34. [Differential diagnosis and therapy examined under the microscope. LUTS (lower urinary tract symptoms) due to OAB (overactive bladder) - a frequent disease picture in the man].
MMW Fortschr Med; 2011 Mar; 153(13):44-5. PubMed ID: 21638816
[No Abstract] [Full Text] [Related]
35. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Singh DV; Mete UK; Mandal AK; Singh SK
J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
[TBL] [Abstract][Full Text] [Related]
36. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
[TBL] [Abstract][Full Text] [Related]
37. Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.
Yoshida M; Sugiyama Y; Masunaga K; Maeda Y; Satoji Y; Nagata T; Inadome A
Drugs Today (Barc); 2007 Jun; 43 Suppl B():1-7. PubMed ID: 17612712
[TBL] [Abstract][Full Text] [Related]
38. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Gallegos PJ; Frazee LA
Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
[TBL] [Abstract][Full Text] [Related]
39. Switch from phytotherapy to tamsulosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
Gross AJ; Busse M; Leonard J; Schumacher H
Prostate Cancer Prostatic Dis; 2005; 8(3):210-4. PubMed ID: 15883586
[TBL] [Abstract][Full Text] [Related]
40. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
Schulman CC
Urology; 2003 Sep; 62(3 Suppl 1):24-33. PubMed ID: 12957197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
